A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop
medications has been shown to be effective in delaying or preventing the progression of
glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field
loss.

This study is being conducted to determine how well DE-126 ophthalmic solution works
(efficacy) in safely lowering IOP when dosed as topical eyedrops. This study will evaluate
the safety and efficacy of four (4) concentrations of DE-126, when compared with latanoprost
(0.005%) eye drops in patients with primary open-angle glaucoma or ocular hypertension.

The IOP will be measured at 3 different times throughout the day, over 6 total visits during
a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop
taking current eye drops to lower IOP). Safety assessments will be done throughout the study,
including ocular signs and symptoms, vital signs, and clinical laboratory tests. While the
most important time-point to measure IOP in this study and evaluate efficacy will be at the
final study visit (month 3), IOP values will also be evaluated at other visits throughout the
3-month treatment period.